Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCLEROCAR: Anti-CD19 CAR T-Cells in Systemic Sclerosis
NCT07493395Phase 2Recruiting
- Sponsor
- CHU Montpellier
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Anti-CD19 CAR T-cells (Beijing Doing Biomedical) in systemic sclerosis (SSc), sponsored by CHU Montpellier. Started Jun 2026; status: recruiting.
02
Drugs
Anti-CD19 CAR T-cells (Beijing Doing Biomedical)
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT07493395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07493395.